Biopharmaceutical company Amgen (NASDAQ: AMGN) has entered into a drug discovery collaboration with US-based PostEra, covering up to five small-molecule programs. As part of the agreement, Amgen will also secure a future option to leverage PostEra’s AI technology for its own pipeline development.
Financial Details and PostEra’s Track Record
While the press release does not disclose the specifics of the upfront and milestone payments or potential sales royalties associated with the agreement, it highlights PostEra’s significant track record, having secured partnerships totaling USD 1 billion to date.
Combining Expertise in the Drug Discovery Project
The collaboration will integrate Amgen’s extensive drug discovery expertise with PostEra’s advanced generative chemistry and synthesis-aware design platform. This platform has demonstrated its capacity to address complex small-molecule discovery programs across a variety of therapeutic areas.- Flcube.com
